We have limited Spanish content available. View Spanish content.

Snap Chart

Weight-loss Drugs Aren't Just Changing Waistlines

A Bain survey shows GLP-1 drugs, like those known as Ozempic or Wegovy, lead to significant changes in consumer behavior that often persist even after consumers stop taking them.

By Emily Miller, Sarah Hershey, and Samantha Gorang

Snap Chart

Weight-loss Drugs Aren't Just Changing Waistlines
en

About the Research

Data powered by Dynata, a leading global first-party data and insights platform.

Industry Expertise

Explore Bain's expertise in Consumer Products and learn how we can help your company.

LEARN MORE
First published in diciembre 2024
Tags

How We've Helped Clients

A Consumer Packaged Goods Company Puts Cost and Complexity Reduction at the Heart of Its Transformation

Read case study

Resetting Shared Services to Save $75 Million

Read case study

Drinking in digital: A leading beverage company stirs a profit from digital strategy

Read case study

Ready to talk?

We work with ambitious leaders who want to define the future, not hide from it. Together, we achieve extraordinary outcomes.

Contact Bain

How can we help you?

See all offices